The Danish diabetes-tech landscape witnessed a major leadership shift today. Rasmus Kofoed officially took over as the new CEO of Hedia on December 1, 2025, marking a pivotal moment for the Copenhagen-based digital therapeutics company. This strategic appointment signals exciting times ahead for people living with diabetes, as Hedia new CEO brings decades of expertise from global healthcare giants.
Hedia new CEO succession comes at a crucial time for the diabetes management industry. The prevalence of diabetes has increased from 8.5% in 2014 to an estimated 11.1% in 2025, while the global diabetes care devices market is projected to reach $61.22 billion in 2030 from $34.30 billion in 2025. With these staggering growth figures, Hedia is well-positioned to capitalize on this expanding market under Rasmus Kofoed’s leadership.
What Makes the Hedia New CEO Appointment So Strategic?
Rasmus Kofoed isn’t your typical corporate executive making a lateral move. The Hedia new CEO brings an impressive track record that reads like a who’s who of life sciences leadership. He has held senior leadership positions at Novo Nordisk, Abbott, Roche and Medtronic, and served as CEO of ChemoMetec. This extensive background gives him unique insights into diabetes management challenges and opportunities.
Furthermore, his leadership change represents more than just replacing one executive with another. He succeeds Lars Christian Lund, who after approximately 2 years in the role has decided to step down to take up a Group CEO position in another international company. This seamless transition demonstrates Hedia’s commitment to maintaining momentum in their growth trajectory.
Danish diabetes-tech company Hedia couldn’t have chosen a better time for this leadership change. The global diabetes devices market size was estimated at $30.31 billion in 2023 and is anticipated to reach $50.33 billion by 2030. Meanwhile, the Hedia new CEO’s experience positions him perfectly to navigate these expanding opportunities.
Hedia’s Position in the Danish Diabetes-Tech Revolution
Understanding Hedia’s current market position helps explain why the Hedia new CEO appointment is so significant. Founded in 2016, the company has positioned itself as a leading European player in digital diabetes management and digital therapeutics, developing digital solutions that help people with insulin‑dependent diabetes to better understand and manage their treatment through data, artificial intelligence and user‑friendly app technology.
The company’s flagship product demonstrates why this Danish diabetes-tech company attracted such high-caliber leadership. Their Hedia Diabetes Assistant is a class IIb medical device designed to support the management of insulin-requiring diabetes, developed in close collaboration with patients, nurses, and other key stakeholders to help patients achieve better health outcomes, including greater stability of blood glucose levels. This collaborative approach aligns perfectly with the Hedia new CEO’s people-focused leadership style.
Moreover, recent developments show Hedia’s growing influence in the diabetes management app space. In January 2025, Glooko and Hedia announced the launch of their interoperable solution, which combines connected care, remote patient monitoring, and digital therapeutic technologies to enhance access for people with Type 1 and Type 2 diabetes. Such strategic partnerships create the perfect foundation for the Hedia new CEO to build upon.
How Rasmus Kofoed’s Experience Transforms Hedia’s Future
The depth of experience the Hedia new CEO brings cannot be overstated. His background spans the entire diabetes care ecosystem. At Medtronic, he was responsible for the company’s diabetes business on a large part of the European markets with approximately 270 employees, held several leading positions within sales and marketing at companies including Roche Diagnostics, Taconic, Abbott as well as several positions in Novo Nordisk for a number of years.
This comprehensive understanding of the diabetes management landscape gives the Hedia new CEO unique insights into what patients really need. His hands-on experience with both multinational corporations and entrepreneurial environments positions him perfectly to scale Hedia’s operations while maintaining their innovative edge.
Additionally, his recent success at ChemoMetec demonstrates his ability to lead technology-driven healthcare companies through periods of transformation. He proved that he is a qualified and engaging leader who achieves results and is capable of developing international organizations with global activities. These qualities are exactly what Hedia needs as they expand their diabetes management app globally.
The Hedia new CEO’s vision extends beyond traditional diabetes care approaches. He stated, “I see enormous potential in Hedia. The company combines clinical insight with technology in a way that creates real value for people with diabetes. I look forward to working with the team to extend our reach, strengthen our partnerships and continue the journey to make Hedia a leading player in digital diabetes care”.
Hedia Leadership Change: Building on Strong Foundations
This Hedia leadership change comes at a time when the company has already established strong market credibility. Under Lars Christian Lund’s leadership, Hedia has progressed from an ambitious start‑up to a professional scale‑up with strong regulatory and commercial development. The Hedia new CEO inherits a company with solid foundations and clear growth potential.
The timing of this Hedia leadership change aligns perfectly with market trends. Advancements in continuous glucose monitoring, flash glucose monitoring, insulin delivery systems, and GLP-1 receptor agonists are reshaping the industry, with the push for more effective, accessible, and patient-friendly treatments driving pharmaceutical and medical device companies to innovate. These trends create perfect opportunities for the Hedia new CEO to leverage the company’s digital-first approach.
Furthermore, recent market developments show increasing demand for integrated solutions. The global Diabetes Care Devices market is witnessing a significant shift towards advanced digital solutions, enhancing patient engagement and improving health outcomes worldwide. This shift plays directly into Hedia’s strengths and provides the Hedia new CEO with tremendous growth opportunities.
The Danish diabetes-tech company’s recent financial backing also strengthens the Hedia new CEO’s position. Hedia has raised €3 million in a seed extension round, supported by existing shareholders and Business Angels, with funding enabling the company to grow its digital health product portfolio and scale its Hedia Diabetes Assistant.
What the Hedia New CEO Means for Patients and Healthcare Providers
For people living with diabetes, the Hedia new CEO appointment signals exciting improvements ahead. His extensive experience with patient-focused solutions across multiple healthcare organizations means he understands the real-world challenges diabetes patients face daily. This patient-centric approach will likely drive further innovations in the Hedia diabetes management app.
Healthcare providers will also benefit from the Hedia new CEO’s leadership. The partnership with Glooko brings algorithm-driven, personalised innovation to diabetes patients and their healthcare teams, providing an alternative for those unable to access insulin pumps and ensuring more effective management of multiple daily injections therapy. Such collaborations demonstrate how the Hedia new CEO’s strategic vision creates value across the entire healthcare ecosystem.
The impact extends beyond individual patient care. Greater integration with telehealth and digital health platforms is enabling remote patient monitoring and real-time data sharing with healthcare providers. Under the Hedia new CEO’s guidance, these capabilities will likely expand, creating more comprehensive diabetes management solutions.
Market Opportunities for the Hedia New CEO
The global market timing couldn’t be better for the Hedia new CEO to make his mark. The global diabetes devices market size accounted for $35.26 billion in 2025 and is projected to hit around $68.75 billion by 2034, growing at a CAGR of 7.7%. This represents massive opportunities for a Danish diabetes-tech company with strong digital capabilities.
Technology trends are also aligning perfectly with Hedia’s strengths. The shift from electrochemical glucose test strips that require fingers to be pricked towards minimally invasive continuous glucose monitors has seen the multibillion-dollar test strip industry in steady decline since the 2010s while CGM companies have experienced consistent growth. The Hedia new CEO’s experience with both traditional and emerging technologies positions him to navigate these transitions successfully.
International expansion opportunities present another key growth vector. The diabetes devices market in Asia Pacific is expected to exhibit the fastest CAGR of 8.95% from 2024 to 2030, attributed to the presence of major market players and increasing prevalence of diabetes. The Hedia new CEO’s international experience makes him well-suited to capture these emerging market opportunities.
Strategic Vision: Where the Hedia New CEO Will Focus
The Hedia new CEO’s strategic priorities are already becoming clear. With this strong commercial experience, he will assume the role as CEO with ambitions to further strengthen Hedia’s product and market platform and expand the company’s international partnerships. This focus on both product development and partnership expansion shows a balanced approach to growth.
Innovation remains central to the Hedia leadership change strategy. Recent developments in the Digital Diabetes Management market reflect rapid growth and transformation, with the market size projected to surpass $20 billion by 2025. The Hedia new CEO’s technology background positions him perfectly to capitalize on these digital transformation opportunities.
Research and development will likely receive increased attention under the Hedia new CEO. Hedia is committed to collecting high-quality clinical data for their Diabetes Assistant, with the next generation of the product under development and soon entering clinical testing. This research-driven approach aligns with the Hedia new CEO’s scientific background and commitment to evidence-based solutions.
Key Takeaways from the Hedia New CEO Appointment
Several critical insights emerge from this Hedia leadership change:
Experience Matters: The Hedia new CEO brings unparalleled diabetes industry experience spanning multiple global organizations and therapeutic areas.
Timing is Perfect: Market conditions, with diabetes prevalence continuing to grow and the International Diabetes Federation reporting an increase from 8.5% in 2014 to an estimated 11.1% in 2025, create ideal conditions for expansion.
Strategic Focus: The emphasis on international partnerships and product platform strengthening shows clear strategic thinking.
Digital-First Approach: The Hedia new CEO’s vision aligns perfectly with industry trends toward digital diabetes management solutions.
Looking Forward: The Future Under Hedia’s New Leadership
As the Hedia new CEO settles into his role, several key developments are likely to emerge. The company will continue to scale their Hedia Diabetes Assistant while launching integrated holistic diabetes management solutions and developing smart AI-enabled algorithms and Software-as-a-Medical Device solutions for chronic metabolic diseases.
The Danish diabetes-tech landscape will undoubtedly benefit from this leadership transition. With the Hedia new CEO’s proven track record and the company’s strong technological foundation, Hedia is well-positioned to become a major player in the global diabetes management app market.
For stakeholders across the diabetes care ecosystem – from patients to healthcare providers to investors – the Hedia new CEO appointment represents a significant positive development. His combination of commercial expertise, technological understanding, and patient-focused vision creates the perfect recipe for transforming diabetes care through innovative digital solutions.
The Hedia leadership change marks more than just a new executive taking charge. It represents the beginning of an exciting new chapter for Danish diabetes-tech innovation, with the potential to improve millions of lives worldwide through better diabetes management technology.
FAQs
Q1: Who is the new CEO of Hedia?
Rasmus Kofoed is the Hedia new CEO, officially taking over on December 1, 2025. He brings extensive experience from Novo Nordisk, Abbott, Roche, Medtronic, and served as CEO of ChemoMetec.
Q2: What makes Rasmus Kofoed qualified to be Hedia’s new CEO?
The Hedia new CEO has decades of experience in life sciences and medtech, including senior leadership positions at major diabetes care companies and proven success in commercial strategy and international expansion.
Q3: What is Hedia and what do they do?
Hedia is a Danish diabetes-tech company founded in 2016 that develops digital solutions for insulin-dependent diabetes management through AI and user-friendly app technology, positioning itself as a leading European player in digital therapeutics.
Q4: Why did the previous CEO of Hedia step down?
Lars Christian Lund, the previous CEO, stepped down after approximately 2 years to take up a Group CEO position at another international company, making way for the Hedia new CEO appointment.
Q5: What are the growth prospects for Hedia under the new CEO?
With the global diabetes devices market projected to reach $68.75 billion by 2034 and diabetes prevalence rising to 11.1% globally, the Hedia new CEO is well-positioned to capitalize on significant growth opportunities.
Q6: How will the Hedia leadership change affect patients?
The Hedia new CEO’s patient-focused approach and experience with diabetes management solutions across multiple organizations should drive further innovations in their diabetes management app and improve patient outcomes.
Q7: What strategic priorities will the new CEO focus on?
The Hedia new CEO plans to strengthen the company’s product and market platform, expand international partnerships, and continue developing innovative digital diabetes management solutions to make Hedia a leading global player.
